Abstract
Prerequisites for successful treatment of severe asthma in children and adolescents with biological drugs are: 1) systematic assessment, excluding and treating other causes of lack of asthma control, 2) immunological phenotyping of the patient, and 3) choice of biological drug targeting the specific disease mechanism. Anti-immunoglobulin (Ig) E and anti-interleukin (IL)-5 have a clinically relevant effect reducing exacerbation rate, but there is still a need for studies in children and adolescents being treated with anti-IgE and anti-IL-5 as well as newer biological drugs, which affect lung function, asthma control and quality of life.
| Bidragets oversatte titel | Biological drugs for treatment of children and adolescents with severe asthma |
|---|---|
| Originalsprog | Dansk |
| Tidsskrift | Ugeskrift for Laeger |
| Vol/bind | 181 |
| Udgave nummer | 6 |
| ISSN | 0041-5782 |
| Status | Udgivet - 4 feb. 2019 |
Emneord
- Adolescent
- Anti-Asthmatic Agents/therapeutic use
- Antibodies, Monoclonal, Humanized
- Asthma/drug therapy
- Biological Products/therapeutic use
- Child
- Humans
- Omalizumab
- Quality of Life